Sofosbuvir-based regimens were well tolerated and cure rates were high in this population.

People with fatty liver disease and obesity who underwent bariatric surgery had better clinical outcomes.

Hepatocellular carcinoma can still occur after hepatitis C is cured, and risk factors differ for people with and without cirrhosis.

Heavy alcohol use during the pandemic was linked to a rise in waiting list registrations and transplants due to alcohol-related hepatitis.

FDA authorizes Evusheld for immunocompromised people who may not respond well to COVID-19 vaccines.

Over the next two decades, obesity-linked NASH will lead to more deaths and high cost in the United States.

Even with this increase, older individuals now have better transplant outcomes.

Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.

HCV treatment initiation dropped by 31% from March to April 2020 and remained low throughout the year.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.